Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina

Thrombosis Research

Volumn 89, Issue 3, 1998, Pages 137-146

  Nishiyama, K ^a   Ogawa, H ^a   Yasue, H ^a   Soejima, H ^a   Misumi, K ^a   Kugiyama, K ^a   Tsuji, I ^b   Kumeda, K ^b  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Coronary spasm; Tissue factor pathway inhibitor

Indexed keywords

ACETYLCHOLINE; HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; AORTA ROOT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY SPASM; CORONARY SINUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN SECRETION; THROMBOGENESIS;

AGED; ANGINA PECTORIS; ANTICOAGULANTS; CORONARY CIRCULATION; CORONARY VASOSPASM; ENDOTHELIUM, VASCULAR; FEMALE; HEPARIN; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 0032004604     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00309-5     Document Type: Article

References (39)

1. 1. Yasue H, Touyama M, Kato H, Tanaka S, Akiyama F. Prinzmetal's variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: Documentation by coronary arteriography. Am Heart J 1976;91:148-55.
2. 2. Oliva PB, Breckinridge JC. Arteriographic evidence of coronary arterial spasm in acute myocardial infarction. Circulation 1977;56:366-74.
3. 3. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
4. 4. Yasue H, Ogawa H, Okumura K. Coronary artery spasm in the genesis of myocardial ischemia. Am J Cardiol 1989;63:29E-32E.
5. 5. Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 1989;80:1617-26.
6. 6. Oshima S, Ogawa H, Yasue H., Okumura K, Matsuyama K, Miyagi H. Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina. J Am Coll Cardiol 1989; 14:150-4.
7. 7. Oshima S, Yasue H, Ogawa H, Okumura K, Matsuyama K. Fibrinopeptide A is released into the coronary circulation after coronary spasm. Circulation 1990;82:2222-5.
8. 8. Kaikita K, Ogawa H, Yasue H, Sakamoto T, Suefuji H, Sumida H, Okumura K. Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation 1995; 92:1726-30.
9. 9. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP 140. Nature 1990;343:757-60.
10. 10. Pearson JD. Vessel wall interactions regulating thrombosis. Br Med Bul 1994;50:776-88.
11. 11. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988;263:6001-4.
12. 12. Broze GJ Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-46.
13. 13. Broze GJ Jr, Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-3.
14. 14. Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985;66:204-12.
15. 15. Hubbard AR, Jennings CA. Inhibition of the tissue fatctor-factor VII complex: Involvement of factor Xa and lipoproteins. Thromb Res 1987;46:527-37.
16. 16. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988;71:335-43.
17. 17. Bajaj MS, Rana SV, Wysoimerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987;79:1874-8.
18. 18. Bajaj MS, Kuppuswanmy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990;87:8869-73.
19. 19. Ameri A, Kuppuswanmy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992;79: 3219-26.
20. 20. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50:803-13.
21. 21. Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: Increased response in cancer patients. Thromb Res 1990;59:651-6.
22. 22. Novotny WF, Palmier M, Wun TC, Broze GJ Jr, Miletich JP. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991;78:394-400.
23. 23. Kokawa T, Abumiya T, Kimura T, Harada-Shiba M, Koh H, Tsushima M, et al. Tissue factor pathway inhibitor activity in human plasma: Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:504-10.
24. 24. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988;72,:2020-5.
25. 25. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: A segment, Gly212-Phe243, of the third Kunitz domain is a heparin binding site. Biochemistry 1995;34: 5725-35.
26. 26. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-Shiba M, Koh H, et al. Measurement of the free form of TFPI antigen in hyperlipidemia: Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996;16:802-8.
27. 27. Yasue H, Horio Y, Nakamura N, Fujii H, Imoto N, Sonoda R, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: Possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986; 74:955-63.
28. 28. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995;118:178-82.
29. 29. Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M, Yonemura H, et al. Amino acid sequence and inhibitory activity of Rhesus monkey tissue factor pathway inhibitor (TFPI): Comparison with human TFPI. J Biochem 1994; 115:708-14.
30. 30. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue-factor pathway inhibitor and lipoproteins: Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994;14:223-9.
31. 31. Van del Wal AC, Becker AE, Van del Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
32. 32. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patients samples. Blood 1991;78:387-93.
33. 33. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1995;15:2055-62.
34. 34. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982;95:355-60.
35. 35. Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann NY Acad Sci 1992;249-58.
36. 36. Levin EG, Marzec U, Anderson J, Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured endothelial cells. J Clin Invest 1984;74:1988-95.
37. 37. Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 1989;72:391-6.
38. 38. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995;92:944-9.
39. 39. Haskel EJ, Torr SR, Day KC, Palmier MO, Wun TC, Sobel BE, Abendshein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991;84:821-7.